Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Identifieur interne : 001850 ( Ncbi/Curation ); précédent : 001849; suivant : 001851Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Auteurs : Norio Sugaya [Japon] ; Yuko Sakai-Tagawa ; Masahiro Bamba ; Rieko Yasuhara ; Masahiko Yamazaki ; Chiharu Kawakami ; Yoshio Yamaguchi ; Yoshiaki Ide ; Masataka Ichikawa ; Keiko Mitamura ; Yoshihiro Kawaoka [États-Unis]Source :
- Antiviral therapy [ 2040-2058 ] ; 2015.
Descripteurs français
- KwdFr :
- Antienzymes (usage thérapeutique), Antiviraux (usage thérapeutique), Cyclopentanes (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Excrétion virale (), Facteurs temps, Femelle, Fièvre (physiopathologie), Fièvre (traitement médicamenteux), Fièvre (virologie), Grippe humaine (physiopathologie), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Guanidines (usage thérapeutique), Humains, Indice de gravité médicale, Mâle, Nourrisson, Oséltamivir (usage thérapeutique), Protéines virales (antagonistes et inhibiteurs), Protéines virales (métabolisme), Résultat thérapeutique, Sialidase (antagonistes et inhibiteurs), Sialidase (métabolisme), Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (croissance et développement), Sous-type H1N1 du virus de la grippe A (enzymologie), Sous-type H1N1 du virus de la grippe A (pathogénicité), Sous-type H3N2 du virus de la grippe A (), Sous-type H3N2 du virus de la grippe A (croissance et développement), Sous-type H3N2 du virus de la grippe A (enzymologie), Sous-type H3N2 du virus de la grippe A (pathogénicité), Zanamivir (analogues et dérivés), Zanamivir (usage thérapeutique).
- MESH :
- analogues et dérivés : Zanamivir.
- antagonistes et inhibiteurs : Protéines virales, Sialidase.
- croissance et développement : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- enzymologie : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- métabolisme : Protéines virales, Sialidase.
- pathogénicité : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- physiopathologie : Fièvre, Grippe humaine.
- traitement médicamenteux : Fièvre, Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Cyclopentanes, Guanidines, Oséltamivir, Zanamivir.
- virologie : Fièvre, Grippe humaine.
- Enfant, Enfant d'âge préscolaire, Excrétion virale, Facteurs temps, Femelle, Humains, Indice de gravité médicale, Mâle, Nourrisson, Résultat thérapeutique, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Child, Child, Preschool, Cyclopentanes (therapeutic use), Enzyme Inhibitors (therapeutic use), Female, Fever (drug therapy), Fever (physiopathology), Fever (virology), Guanidines (therapeutic use), Humans, Infant, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (enzymology), Influenza A Virus, H1N1 Subtype (growth & development), Influenza A Virus, H1N1 Subtype (pathogenicity), Influenza A Virus, H3N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (enzymology), Influenza A Virus, H3N2 Subtype (growth & development), Influenza A Virus, H3N2 Subtype (pathogenicity), Influenza, Human (drug therapy), Influenza, Human (physiopathology), Influenza, Human (virology), Male, Neuraminidase (antagonists & inhibitors), Neuraminidase (metabolism), Oseltamivir (therapeutic use), Severity of Illness Index, Time Factors, Treatment Outcome, Viral Proteins (antagonists & inhibitors), Viral Proteins (metabolism), Virus Shedding (drug effects), Zanamivir (analogs & derivatives), Zanamivir (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Zanamivir.
- chemical , antagonists & inhibitors : Neuraminidase, Viral Proteins.
- chemical , metabolism : Neuraminidase, Viral Proteins.
- chemical , therapeutic use : Antiviral Agents, Cyclopentanes, Enzyme Inhibitors, Guanidines, Oseltamivir, Zanamivir.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Virus Shedding.
- drug therapy : Fever, Influenza, Human.
- enzymology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- growth & development : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- pathogenicity : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- physiopathology : Fever, Influenza, Human.
- virology : Fever, Influenza, Human.
- Child, Child, Preschool, Female, Humans, Infant, Male, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.
DOI: 10.3851/IMP2798
PubMed: 24832015
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000830
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000830
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000671
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001850
Links to Exploration step
pubmed:24832015Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.</title>
<author><name sortKey="Sugaya, Norio" sort="Sugaya, Norio" uniqKey="Sugaya N" first="Norio" last="Sugaya">Norio Sugaya</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan. sugaya47@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pediatrics, Keiyu Hospital, Yokohama</wicri:regionArea>
<wicri:noRegion>Yokohama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sakai Tagawa, Yuko" sort="Sakai Tagawa, Yuko" uniqKey="Sakai Tagawa Y" first="Yuko" last="Sakai-Tagawa">Yuko Sakai-Tagawa</name>
</author>
<author><name sortKey="Bamba, Masahiro" sort="Bamba, Masahiro" uniqKey="Bamba M" first="Masahiro" last="Bamba">Masahiro Bamba</name>
</author>
<author><name sortKey="Yasuhara, Rieko" sort="Yasuhara, Rieko" uniqKey="Yasuhara R" first="Rieko" last="Yasuhara">Rieko Yasuhara</name>
</author>
<author><name sortKey="Yamazaki, Masahiko" sort="Yamazaki, Masahiko" uniqKey="Yamazaki M" first="Masahiko" last="Yamazaki">Masahiko Yamazaki</name>
</author>
<author><name sortKey="Kawakami, Chiharu" sort="Kawakami, Chiharu" uniqKey="Kawakami C" first="Chiharu" last="Kawakami">Chiharu Kawakami</name>
</author>
<author><name sortKey="Yamaguchi, Yoshio" sort="Yamaguchi, Yoshio" uniqKey="Yamaguchi Y" first="Yoshio" last="Yamaguchi">Yoshio Yamaguchi</name>
</author>
<author><name sortKey="Ide, Yoshiaki" sort="Ide, Yoshiaki" uniqKey="Ide Y" first="Yoshiaki" last="Ide">Yoshiaki Ide</name>
</author>
<author><name sortKey="Ichikawa, Masataka" sort="Ichikawa, Masataka" uniqKey="Ichikawa M" first="Masataka" last="Ichikawa">Masataka Ichikawa</name>
</author>
<author><name sortKey="Mitamura, Keiko" sort="Mitamura, Keiko" uniqKey="Mitamura K" first="Keiko" last="Mitamura">Keiko Mitamura</name>
</author>
<author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Madison (Wisconsin)</settlement>
<region type="state">Wisconsin</region>
</placeName>
<orgName type="university" n="3">Université du Wisconsin à Madison</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:24832015</idno>
<idno type="pmid">24832015</idno>
<idno type="doi">10.3851/IMP2798</idno>
<idno type="wicri:Area/PubMed/Corpus">000830</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000830</idno>
<idno type="wicri:Area/PubMed/Curation">000830</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000830</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000671</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000671</idno>
<idno type="wicri:Area/Ncbi/Merge">001850</idno>
<idno type="wicri:Area/Ncbi/Curation">001850</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.</title>
<author><name sortKey="Sugaya, Norio" sort="Sugaya, Norio" uniqKey="Sugaya N" first="Norio" last="Sugaya">Norio Sugaya</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan. sugaya47@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pediatrics, Keiyu Hospital, Yokohama</wicri:regionArea>
<wicri:noRegion>Yokohama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sakai Tagawa, Yuko" sort="Sakai Tagawa, Yuko" uniqKey="Sakai Tagawa Y" first="Yuko" last="Sakai-Tagawa">Yuko Sakai-Tagawa</name>
</author>
<author><name sortKey="Bamba, Masahiro" sort="Bamba, Masahiro" uniqKey="Bamba M" first="Masahiro" last="Bamba">Masahiro Bamba</name>
</author>
<author><name sortKey="Yasuhara, Rieko" sort="Yasuhara, Rieko" uniqKey="Yasuhara R" first="Rieko" last="Yasuhara">Rieko Yasuhara</name>
</author>
<author><name sortKey="Yamazaki, Masahiko" sort="Yamazaki, Masahiko" uniqKey="Yamazaki M" first="Masahiko" last="Yamazaki">Masahiko Yamazaki</name>
</author>
<author><name sortKey="Kawakami, Chiharu" sort="Kawakami, Chiharu" uniqKey="Kawakami C" first="Chiharu" last="Kawakami">Chiharu Kawakami</name>
</author>
<author><name sortKey="Yamaguchi, Yoshio" sort="Yamaguchi, Yoshio" uniqKey="Yamaguchi Y" first="Yoshio" last="Yamaguchi">Yoshio Yamaguchi</name>
</author>
<author><name sortKey="Ide, Yoshiaki" sort="Ide, Yoshiaki" uniqKey="Ide Y" first="Yoshiaki" last="Ide">Yoshiaki Ide</name>
</author>
<author><name sortKey="Ichikawa, Masataka" sort="Ichikawa, Masataka" uniqKey="Ichikawa M" first="Masataka" last="Ichikawa">Masataka Ichikawa</name>
</author>
<author><name sortKey="Mitamura, Keiko" sort="Mitamura, Keiko" uniqKey="Mitamura K" first="Keiko" last="Mitamura">Keiko Mitamura</name>
</author>
<author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Madison (Wisconsin)</settlement>
<region type="state">Wisconsin</region>
</placeName>
<orgName type="university" n="3">Université du Wisconsin à Madison</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral therapy</title>
<idno type="eISSN">2040-2058</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cyclopentanes (therapeutic use)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Female</term>
<term>Fever (drug therapy)</term>
<term>Fever (physiopathology)</term>
<term>Fever (virology)</term>
<term>Guanidines (therapeutic use)</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H1N1 Subtype (enzymology)</term>
<term>Influenza A Virus, H1N1 Subtype (growth & development)</term>
<term>Influenza A Virus, H1N1 Subtype (pathogenicity)</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H3N2 Subtype (enzymology)</term>
<term>Influenza A Virus, H3N2 Subtype (growth & development)</term>
<term>Influenza A Virus, H3N2 Subtype (pathogenicity)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (physiopathology)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Neuraminidase (metabolism)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (metabolism)</term>
<term>Virus Shedding (drug effects)</term>
<term>Zanamivir (analogs & derivatives)</term>
<term>Zanamivir (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Cyclopentanes (usage thérapeutique)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Excrétion virale ()</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Fièvre (physiopathologie)</term>
<term>Fièvre (traitement médicamenteux)</term>
<term>Fièvre (virologie)</term>
<term>Grippe humaine (physiopathologie)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Guanidines (usage thérapeutique)</term>
<term>Humains</term>
<term>Indice de gravité médicale</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Oséltamivir (usage thérapeutique)</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Protéines virales (métabolisme)</term>
<term>Résultat thérapeutique</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Sialidase (métabolisme)</term>
<term>Sous-type H1N1 du virus de la grippe A ()</term>
<term>Sous-type H1N1 du virus de la grippe A (croissance et développement)</term>
<term>Sous-type H1N1 du virus de la grippe A (enzymologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (pathogénicité)</term>
<term>Sous-type H3N2 du virus de la grippe A ()</term>
<term>Sous-type H3N2 du virus de la grippe A (croissance et développement)</term>
<term>Sous-type H3N2 du virus de la grippe A (enzymologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (pathogénicité)</term>
<term>Zanamivir (analogues et dérivés)</term>
<term>Zanamivir (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuraminidase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Cyclopentanes</term>
<term>Enzyme Inhibitors</term>
<term>Guanidines</term>
<term>Oseltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Virus Shedding</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fever</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines virales</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Fièvre</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Fever</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fièvre</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term>
<term>Antiviraux</term>
<term>Cyclopentanes</term>
<term>Guanidines</term>
<term>Oséltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Fièvre</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Fever</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Excrétion virale</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité médicale</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Résultat thérapeutique</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001850 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001850 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:24832015 |texte= Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24832015" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
This area was generated with Dilib version V0.6.34. |